Popular Articles
Burdock Root

Hospitals Receive AHA Award For Improving Community Health Through Effective Collaborative Projects
The American Hospital Association (AHA) announced the winners of the AHA NOVA Award. These five collaborative hospital-led programs work to improve community health by improving health habits and other social and educational factors leading to better health status and improving access to care. Each program will be honored at a July 25 ceremony held during the association"s annual Health Forum Leadership Summit in San Francisco.
generic viagra online
Revance Therapeutics Announces Efficacy Of Topical Botulinum Toxin Type A For The Treatment Of Facial Wrinkles
Revance Therapeutics, Inc. ("Revance") announces that RT001, a topical botulinum toxin type A, under investigation for the treatment of crow"s feet wrinkles, demonstrated efficacy and safety in a US Phase 2b clinical study. The randomized, double-blind, parallel-group, dose-finding study showed efficacy versus placebo at primary and multiple secondary endpoints.
News of the day
Unjust Stigma, Lack Of Physician Training Hinder Market For IUDs, Opinion Piece Says
Intrauterine devices "seem like the perfect form of contraception: simple to use, long-lasting, reversible, hormone-free, economical," Slate columnist Kate Klonick writes. She asks, "So why are American women so late to this party? Perhaps the better question is: Why did they leave the party to begin with?"Klonick explains the benefits of IUDs, calling them a "foolproof method of birth control" and noting that they are 99% effective and "can last up to 10 years." Although IUDs can cost between $300 and $500, it is a one-time expense that is often covered by insurance, according to Klonick. She notes that although efficacy studies show that birth control pills, patches and vaginal rings can be "99% effective in a clinical setting, real-life compliancy -- like forgetting to take the pill at the same time every day -- reduces its success rate." Klonick adds that the availability of hormone-free IUDs makes them an "ideal" option for "women prone to some of the negative effects of hormonal birth control, like weight gain, mood swings, acne or high blood pressure."According to Klonick, IUDs were used by almost 10% of U.S. women taking birth control in the late 1970s but are now used by less than 2% of such women. She writes that Katharine O"Connell, a gynecologist at Columbia University who specializes in contraception, believes IUDs still carry a stigma "due to the erroneous belief that they"re highly dangerous" partly due to a number of deaths that occurred in the early 1970s tied to a specific brand of IUD known as the Dalkon Shield. Because of bad publicity surrounding the devices, "the U.S. pharmaceutical industry abandoned the research and manufacturing of IUDs in the mid-1980s, claiming the devices were no longer profitable," Klonick states. According to O"Connell, most experts now agree that the Dalkon Shield"s problems were related to its design, which made users more susceptible to infection, and a lack of testing for sexually transmitted infections before insertion.There are now two major brands of IUDs -- Mirena and ParaGard -- on the U.S. market, but physican training remains a problem, according to Klonick. She writes that studies show that premedical students are not educated regarding IUDs to the extent they are about oral contraceptive pills. O"Connell also noted that many medical schools limit classes on contraception to one lecture, which often omits IUDs. Klonick writes, "This lack of training can leave many doctors feeling uncomfortable recommending the once-controversial devices to their patients." She adds that many physicians who know how to insert and remove IUDs "still refuse to recommend it to childless patients because of the device"s checkered history." She concludes, "With Mirena advertising on television, the downturn in the economy forcing people to economize, and more women concerned about the long-term effects hormones have on their bodies, perhaps the IUD"s stigma will finally become a thing of the past" (Klonick, Slate, 7/29).
Cardiovascular

Hot Flashes May Prompt Closer Look At Bone Health

A new study, published in the journal Menopause, found postmenopausal women with vasomotor symptoms-which include hot flashes and night sweats-had lower bone mineral density in the spine and hip. Researchers at the University of California, Los Angeles, and colleagues analyzed data from over two thousand women between the ages of forty-two to fifty-two who participated in the bone sub-study of the Study of Women"s Health Across the Nation. The authors of the UCLA study also found premenopausal women and early perimenopausal women who had vasomotor symptoms were found to have lower femoral neck bone mineral density than those without vasomotor symptoms. According to bone expert, Warren Levy, PhD, although the extent of correlation varied depending on the stage of menopause and the frequency of vasomotor symptoms, the findings did support earlier studies by others that have suggested an association between low estradiol levels, vasomotor symptoms, and low bone density. "The concept of assessing bone health via the amount or intensity of hot flashes is interesting and may provide another method for screening for osteoporosis," suggests Dr. Levy, who is also CEO of Unigene Laboratories Inc. , a biopharmaceutical company focused on peptide-based nasally and orally delivered osteoporosis treatments. "However, the gold standard today is a bone scan which is widely available and inexpensive for most patients. The study does help raise awareness about the importance of being vigilant about bone loss during this part of one"s life, and encourages regular bone scans, if possible, because even early perimenopausal women can experience significant bone loss." Some patients may opt to wait out their hot flashes so as not to take estrogen supplementation. "We hope that the new findings will encourage physicians and patients to also consider the various treatment options that are available without the use of estrogen-based products," says Dr. Levy, who believes that as life expectancy rates continue to rise, osteoporosis will have a greater impact on national health and quality of life. "If there are acceptable alternatives for patients with osteoporosis or low bone density, the side effect/safety profile of each drug should be considered carefully before treatment decisions are made." For more information, log on to http://www.unigene.com. Unigene Laboratories Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):